Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Bristol-Myers Squibb | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
The overall goal of this study is to identify risk and prognosis factors of Interstitial Lung Disease (ILD) in patients with rheumatoid arthritis (RA).
This is not an interventional study. This is a study designed to recruit individuals affected by RA and investigate associated ILD to better understand the clinical phenotypes and genetic/molecular endotypes of RAILD, including the prognosis of the disease.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Rheumatoid arthritis - Interstitial lung disease patients | Assessment are as follows :
| ||
| Rheumatoid arthritis - no Interstitial lung disease patients | Assessment are as follows :
|
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Identification of genetic factors implicated in RA-ILD using whole exome sequencing (WES). | whole exome sequencing data | Baseline |
| Measure | Description | Time Frame |
|---|---|---|
| Identification of genetic factors implicated in RA-ILD using genome wide association study. | genome wide sequencing data | Baseline |
| Describe RA-ILD natural history by a 5 years annual follow up of RA-ILD patients. |
Not provided
SELECTION OF CASES :
Inclusion Criteria:
Exclusion Criteria:
- Lack of signed informed consent
SELECTION OF CONTROLS:
Inclusion Criteria:
Exclusion Criteria:
- Lack of signed informed consent
Not provided
Not provided
Not provided
The population of interest are individuals affected by RA with ILD (RA-ILD). Individuals affected with RA and without ILD (RA-noILD) will be included as a control population. The ILD status being systematically assessed by HRCT chest scan.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Philippe DIEUDE, MD, PhD | Assistance Publique - Hôpitaux de Paris | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Bichat Hospital | Paris | 75018 | France |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41110685 | Derived | Juge PA, Debray MP, Pensec VD, Richez C, Avouac J, Wemeau-Stervinou L, Flipo RM, Nunes H, Saidenberg-Kermanac'h N, Gottenberg JE, Jouneau S, Constantin A, Cottin V, Marotte H, Soubrier M, Fautrel B, Nocturne G, Richette P, Berenbaum F, Zylberman-Yona H, Gorenne I, Bancal C, Borie R, Ebstein E, Forien M, Ottaviani S, Crestani B, Dieude P. Baseline characteristics of the TRANSLATE2 cohort: A prospective study on rheumatoid arthritis-associated interstitial lung disease. Joint Bone Spine. 2026 Mar;93(2):105991. doi: 10.1016/j.jbspin.2025.105991. Epub 2025 Oct 17. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001172 | Arthritis, Rheumatoid |
| D017563 | Lung Diseases, Interstitial |
| ID | Term |
|---|---|
| D001168 | Arthritis |
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
| D012216 | Rheumatic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
blood DNA, blood mRNA, serum
Decline of pulmonary functional tests (PFT) as well as changes in High-Resolution Computed-Tomography chest scan scores
| Every year during 5 years |
| Description of the effect of disease modifying Anti Rheumatic Drugs (DMARDs) on ILD course and mortality. | Influence of treatment (DMARDs and biologics) over RA-ILD course estimated annually given the cumulated dosage received. | Every year during 5 years |
| D003240 |
| Connective Tissue Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |